FDA Weighs Lilly, Amgen Findings On Cancer Drugs

Law360, New York (December 12, 2008, 12:00 AM EST) -- The U.S. Food and Drug Administration has asked an advisory committee to consider whether clinical studies by Amgen Inc. and ImClone Systems Inc. are strong enough to show that their respective cancer drugs, Vectibix and Erbitux, are more likely to help patients with a nonmutated rather than a mutated form of a certain gene.

Amgen and ImClone have found that people who have metastatic colorectal cancer, or colon cancer that has spread, and the “wild type” of the gene KRAS appear to respond better to their...
To view the full article, register now.